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Thrombin is a novel regulator of hexokinase activity in mesan- Hexokinases (HKs) are fundamentally important to all
gial cells. cells. By catalyzing the phosphorylation of glucose (Glc)
Background. Hexokinase (HK) activity is fundamentally to yield Glc-6-P, they play a central role in both the
important to cellular glucose uptake and metabolism. Phorbol
facilitated uptake and subsequent metabolism of Glc. Inesters increase both HK activity and glucose utilization in cul-
the insulin-sensitive peripheral tissues that account fortured mesangial cells via a protein kinase C (PKC)- and extra-
the bulk of systemic Glc uptake and utilization (that is,cellular signal-regulated kinases 1 and 2 (ERK1/2)-dependent
mechanism. In adult kidneys, increased HK activity has been skeletal muscle and adipose), insulin is a major regulator
reported in both glomerular injury and in diabetes, but the mech- of Glc metabolism and HK activity. In contrast, the kid-
anisms responsible for these changes are unknown. Thrombin, ney does not depend on insulin for normal Glc metabo-
a known activator of both PKC and ERK1/2, is increased in lism and is characterized by a state of Glc overutilization
the settings of renal injury and diabetes. Thus, thrombin may
in the setting of diabetes, which differs markedly fromcontribute to the observed changes in HK activity in vivo.
the state of Glc underutilization observed in diabeticMethods. Thrombin and thrombin receptor agonists were
muscle and adipose tissue [1–10]. It is therefore of greattested for the ability to increase HK activity and glucose metab-
olism in murine mesangial (SV40 MES 13) cells. ERK1/2 acti- interest that increased renal HK activity has been re-
vation was also evaluated in parallel. Thrombin inhibition ported not only in experimental diabetes, but also in
(hirudins), PKC depletion, Ser-Thr kinase inhibition (H-7), genetic obesity [8], compensatory renal hypertrophy [9],
MEK1/2 inhibition (PD98059), pertussis toxin (PTX), and gen-
and puromycin aminonucleoside nephrosis [11]. The mo-eral inhibitors of transcription or translation were then tested
lecular mechanisms underlying these changes and thefor the ability to attenuate these effects.
normal determinants of HK activity in the kidney, how-Results. Thrombin ($0.01 U/mL) mimicked the effect of
phorbol esters, increasing HK activity .50% within 12 to 24 ever, are not known. Moreover, the contributions of indi-
hours (P , 0.05). This effect was inhibited by hirudins, mim- vidual cell types to these changes have not been ad-
icked by thrombin receptor agonists, and accompanied by in- dressed. As the principal renal cell type affected by a
creased Glc utilization. H-7, PD98059, and general inhibitors
variety of pathologic conditions, including diabetes, weof transcription or translation—but not PTX—prevented
are particularly interested in the regulation of HK activ-thrombin-induced HK activity at 24 hours. PKC depletion and
ity in mesangial cells.PD98059 also blocked the associated phosphorylation and acti-
vation of ERK1/2. In preliminary testing, several known regulators of
Conclusions. Thrombin increases mesangial cell HK activity HK activity in extrarenal tissues (for example, insulin
via a PTX-insensitive mechanism involving thrombin receptor [12], adrenomimetics [13], and glucocorticoids [14]) were
activation, PKC-dependent activation of ERK1/2, and both found to have no significant effect on HK activity in
ongoing gene transcription and de novo protein synthesis. As
cultured mesangial cells (R.B. Robey, unpublished ob-such, thrombin is a novel regulator of HK activity in mesangial
servations), suggesting that this cell type may exhibitcells and may play a role in coupling renal injury to metabolism.
novel regulatory characteristics with regard to Glc-phos-
phorylating capacity. Compatible with this interpreta-
tion, we recently reported the novel regulation of mesan-Key words: hexokinase, glucose, protein kinase C, extracellular signal-
regulated kinases 1 and 2, renal injury. gial cell HK activity by phorbol esters [15]. The ability
of phorbol esters to increase HK activity required the
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diates that are capable of altering mesangial cell HK Cell culture
activity in vivo, however, are not known. Mycoplasma-free SV40 MES 13 (murine mesangial)
The neutral serine protease a-thrombin (thrombin) is cells were obtained from the American Type Culture
a potent mesangial cell mitogen and is a known activator Collection (Rockville, MD, USA) at passage 27. These
of both PKC [16] and the classic mitogen-activated pro- cells are derived from glomerular explants of SV40 trans-
tein kinase (MAPK or ERK1/2) pathway [17]. Interest- genic mice and exhibit both biochemical and morpho-
ingly, thrombin has also been shown to stimulate Glc logic features of normal mesangial cells in culture [15, 23].
uptake and utilization in platelets [18, 19], which strongly Cells were maintained in DME:F12 (3:1) medium contain-
express the protease-activated receptor type 1 (PAR1) ing 6 mmol/L Glc and were supplemented with both 14
thrombin receptor [20]. This receptor is proteolytically mmol/L HEPES and 5% fetal bovine serum. Cells were
routinely grown to confluence in a humidified 378C/5%activated by thrombin via targeted cleavage of its extra-
CO2 incubator before testing, and all experiments reportedcellular NH2-terminus, resulting in a new NH2-terminal
herein were performed between passages 30 and 40 to“tethered ligand” capable of receptor activation via an
minimize the effects of phenotypic variation in continu-intramolecular mechanism [20]. PAR1 is also strongly
ous culture. Where appropriate, cells were serum-expressed by mesangial cells and has been shown to
deprived for 24 hours prior to and during testing. Whenmediate a number of thrombin’s cellular effects in this
inhibitors were employed, cells were typically pretreatedcell type [21, 22], but the effects of thrombin and PAR1
with inhibitor alone for 30 to 60 minutes before testing.activation on Glc metabolism and on HK activity in
particular have not been described. We therefore tested
Hexokinase assaysthe ability of PAR1 activation by thrombin to alter HK
Hexokinase activity was measured as the total Glc-activity in cultured mesangial cells.
phosphorylating capacity of whole cell extracts using a
standard G6PDH-coupled assay [24]. In brief, cell lysates
METHODS were prepared by a modification of the method of O’Do-
herty et al [25] in 900 mmol/L KCl, 20 mmol/L MgCl2,Reagents
10 mmol/L ethylenediaminetetraacetic acid (EDTA),Bordetella pertussis toxin (PTX) was obtained from
11.1 mmol/L monothioglycerol, 0.25% Triton X-100, 10Calbiochem (La Jolla, CA, USA), as were the specific
mmol/L Glc, and 20 mmol/L Tris·HCl, pH 8.1, as de-MEK1/2 inhibitor PD98059 and the recombinant hirudin
scribed previously [15]. Freshly prepared aliquots werevariant [Lys33/Arg36/Arg47]-rHV1. Dichloro-1-b-D-ribofur-
then assayed spectrophotometrically for the Glc- andanosylbenzimidazole (DRB) was obtained from Fluka
ATP-dependent reduction of NADP in the presence of
(Milwaukee, WI, USA), and yeast Glc-6-phosphate de-
excess G6PDH (the final assay mixture composition was
hydrogenase (G6PDH) was obtained from Boehringer
1 U/mL G6PDH, 0.5 mg/mL NADP, 6.7 mmol/L ATP,
Mannheim (Indianapolis, IN, USA). All cell culture re- 7.7 mmol/L MgCl, 4.2 mmol/L Glc, 45 mmol/L KCl, 1
agents, including serum and additives, were supplied by mmol/L NaH2PO4, 10.6 mmol/L monothioglycerol, 0.01%GIBCO BRL (Gaithersburg, MD, USA). The hexapep- Triton X-100, 0.5 mmol/L EDTA acid, and 42 mmol/L
tide PAR4 thrombin receptor agonist (GYPGKF) used Tris·HCl, pH 8.5). All assays were performed at 258C
in these studies corresponds to the NH2-terminal teth- under conditions of linear HK-limited NADPH forma-
ered ligand of proteolytically activated murine PAR4 tion, and total HK activity, normalized for cellular pro-
(MmPAR433/38) and was the generous gift of Dr. Trevor tein content, was expressed as the Glc phosphorylation
Walker (University of Edinburgh, Edinburgh, UK). The rate relative to paired unstimulated controls [15].
corresponding PAR1 hexapeptide agonist (SFLLRN) is
identical to the human PAR1-tethered ligand (HsP- Extracellular signal-regulated kinases 1 and 2
phosphorylation and activity assaysAR150/55) and was obtained from Advanced ChemTech
(Louisville, KY, USA). All other reagents, including Extracellular signal-regulated kinases 1 and 2 phosphor-
high-activity bovine a-thrombin, the recombinant leech ylation was evaluated by immunoblot analysis of whole
hirudin variant [Lys47]-rHV2, phorbol 12-myristate 13- cell lysates using specific monoclonal antibodies directed
acetate (PMA), phorbol-12,13-didecanoate (PDD), 4a- against a common ERK1/2 epitope (total ERK1/2) and
phorbol-12,13-didecanoate (4a-PDD), H-7 (1-(5-Isoqui- the dual-phosphorylated tripeptide motif of ERK1/2
nolinesulfonyl)-2-methylpiperazine·HCl), cycloheximide (phospho-ERK1/2) as described previously [15]. The
(CHX), NADP, ATP, and the 14-mer PAR1 agonist corresponding ERK1/2 phosphotransferase activity was
peptide HsPAR142/55 (SFLLRNPNDKYEPF), were ob- measured by a specific immunopreciptated kinase (IP/
tained from Sigma (St. Louis, MO, USA), unless other- kinase) activity assay using a commercially available kit
(New England BioLabs, Beverly, MA, USA) accordingwise noted, and were of the finest quality available.
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to the manufacturer’s recommendations. In brief, acti-
vated ERK1/2 immunoprecipitates were prepared from
cell lysates using immobilized monoclonal antibodies di-
rected against dual-phosphorylated (that is, activated)
ERK1/2. Immunoprecipitates were then assayed for the
ability to specifically Ser phosphorylate an Elk-1 fusion
protein in vitro. Total phosphotransferase activity was
assessed by immunoblotting with rabbit polyclonal IgG
specific for phospho-Elk-1 (Elk-1-P) followed by chemi-
luminescent detection using horseradish peroxidase-con-
jugated antirabbit secondary antibodies and the Phototo-
pet-HRP Western Detection System (New England
BioLabs). An Eagle-Eyet II still videoimaging system
(Stratagene, La Jolla, CA, USA) was employed for auto-
radiogram image acquisition, and analysis of the result-
ing digital images was performed using NIH Image ver-
sion 1.61 software for Macintosh computers (National
Institutes of Health, Bethesda, MD, USA). Control IP/
kinase assays were routinely performed in parallel using
unstimulated cell lysates with and without the addition Fig. 1. Thrombin increases mesangial cell hexokinase (HK) activity in
a time-dependent fashion. Thrombin (1 U/mL) increased HK activityof functional MEK-activated recombinant ERK2.
approximately 20% within six hours and as much as approximately
50% above basal levels during maximal induction observed between 12Glucose utilization and lactate production assays and 24 hours (*P , 0.03). All data are presented as the mean 6 SEM
for at least four independent measures.Glucose utilization and lactate production were as-
sayed as the net disappearance of Glc and the net accu-
mulation of lactate in the culture medium, respectively.
Cells were routinely tested in defined growth medium depicted in Figure 1, the maximal HK induction was
containing 6 mmol/L Glc and lacking phenol red. At observed within 12 to 24 hours of exposure to 1 U/mL
appropriate time points, medium aliquots were assayed thrombin. Although HK activity began to decline there-
spectrophotometrically for both Glc and lactate content after, the total activity of stimulated cells was still at
via standard enzymatic coupled reactions as described
least 10 to 15% higher than unstimulated controls at 36
previously [15]. Glc was assayed by spectrophotometric
hours (data not shown). As shown in Figure 2, the effect
monitoring of chromagen formation coupled to Glc oxi-
of thrombin at 24 hours was concentration dependent,dase [26], and the lactate assay was based on similar
with significant increases in HK activity uniformly ob-chromagen formation coupled to lactate oxidase. All
served at thrombin activities .0.001 U/mL (P , 0.05)measures of medium Glc and lactate content were per-
and a plateau effect, with increases of as much as 40 toformed in the presence of nonlimiting concentrations of
50% observed between 0.01 and 10.0 U/mL. PreliminaryGlc and under conditions of linear net Glc utilization
testing in cultured rat mesangial cells and an SV40-trans-and lactate accumulation.
formed human mesangial (C2M15) cell line that also
exhibits biochemical and morphologic features of normalStatistical analysis
mesangial cells in culture [27] yielded similar resultsData are presented as the mean 6 SEM of at least
(data not shown). To better understand the molecularthree independent experiments unless otherwise noted.
mechanisms underlying these responses, we further char-Statistical comparisons were performed by analysis of
acterized the response in SV40 MES 13 cells exposed tovariance (ANOVA) or paired t-testing where appro-
1 U/mL thrombin for 24 hours.priate using a significance level of 95% and StatView 5.0
software for Macintosh computers (SAS Institute, Cary,
Hirudins inhibit thrombin-induced mesangial cellNC, USA).
HK activity
To evaluate the specificity of thrombin’s effect on mes-
RESULTS angial cell HK activity, we tested recombinant leech hiru-
Thrombin increases mesangial cell HK activity in a dins for the ability to inhibit this effect. These proteins
time- and dose-dependent manner specifically bind to the active site of thrombin and
thereby inhibit its proteolytic activity. As shown in Fig-Thrombin increased total HK activity in SV40 MES
13 cells in both a time- and dose-dependent manner. As ure 3, the recombinant type 2 hirudin variant [Lys47]-
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Fig. 2. Thrombin exhibits a dose-dependent effect on mesangial cell
HK activity. Thrombin significantly increased total HK activity in cul-
tured mesangial cells exposed to thrombin activities . 0.001 U/mL for
24 hours (*P , 0.05 vs. unstimulated controls). Data are presented as
the mean 6 SEM for at least four independent measures, and all
thrombin activities are reported in NIH units defined as specific proteo-
lytic activity in a standardized assay relative to a thrombin reference
standard.
rHV2 inhibited thrombin-induced (Fig. 3A), but not
basal (Fig. 3B) HK activity. Another recombinant hiru-
din variant, [Lys33/Arg36/Arg47]-rHV1, was also tested
with similar results (data not shown), further suggesting
specificity for thrombin.
PAR1 thrombin receptor agonists mimic thrombin’s
effect on HK activity
The PAR1 thrombin receptor activator peptides
HsPAR150/55 (SFLLRN) and HsPAR142/55 (SFLLRNPND
KYEPF) each correspond to the NH2-terminus of pro-
teolytically activated human PAR1 and have been shown Fig. 3. Hirudins inhibit thrombin-induced (A), but not basal (B), mes-
angial cell HK activity. To assess the specificity of our observations,to specifically mimic the effect of proteolytic PAR1 acti-
we tested the ability of hirudins to inhibit HK induction by 1 U/mLvation. As shown in Figure 4, HsPAR142/55 mimicked the
bovine thrombin. The recombinant type 2 hirudin variant [Lys47]-rHV2
effect of thrombin on mesangial cell HK activity. Similar (rHV2) inhibited thrombin-induced HK activity in a dose-dependent
fashion (A), whereas basal HK activity remained unaffected (B). Theresults were obtained with the hexapeptide agonist
depicted data represent the mean 6 SEM of at least four independentHsPAR150/55 (data not shown). In contrast, the PAR4- experiments (†P , 0.02 and *P , 0.04 vs. thrombin-stimulated controls).
activating hexapeptide MmPAR460/65, corresponding to
the murine PAR4-tethered ligand sequence (GYPGKF),
had no significant effect on HK activity. Exposure to 1,
(N 5 3, P 5 NS) of unstimulated control cells, respec-10, 100, 200, or 500 mmol/L MmPAR460/65 for 24 hours
tively. In contrast, cells exposed to 1 U/mL thrombinresulted in total HK activities that were 93 6 3% (N 5
and tested in parallel increased total HK activity by ap-3, P 5 NS), 101 6 8% (N 5 3, P 5 NS), 102 6 8% (N 5
3, P 5 NS), 108 6 5% (N 5 4, P 5 NS), and 111 6 9% proximately 30% (P , 0.05).
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70% (P , 0.05), consistent with a postreceptor role for
Ser-Thr kinases such as PKC in mediating this effect.
Basal HK activity was also slightly, albeit significantly,
affected by H-7 at this concentration, suggesting that
Ser-Thr kinase signaling intermediates such as PKC may
also play a small role in the maintenance of basal activity.
These changes were not accompanied by alterations in
the cellular exclusion of trypan blue (data not shown),
suggesting that they are not primarily attributable to
changes in cell viability.
Thrombin increases HK activity via a classic MAPK
pathway-dependent mechanism
We have previously shown that the specific MEK1/2
inhibitor PD98059 is capable of blocking the induction
of HK activity by phorbol esters [15]. We therefore tested
the ability of MEK1/2 inhibition to similarly block HK
induction by thrombin. As demonstrated previously for
phorbol esters, 50 mmol/L PD98059 completely pre-Fig. 4. PAR1 thrombin receptor peptide agonists mimic the effect of
thrombin on HK activity. The specific PAR1 peptide agonist HsPAR142/55 vented the induction of HK activity by 1 U/mL thrombin
(SFLLRNPNDKYEPF) increased HK activity in a dose-dependent at 24 hours: Total HK activities in the presence or ab-manner ( ) and fully mimicked the effect of 1 U/mL thrombin (j) at
sence of PD98059 were 102 6 7% and 134 6 8% of24 hours (*P , 0.003 and †P , 0.04 vs. unstimulated controls). Data
are presented as the mean 6 SEM for at least three independent unstimulated control values (P , 0.02), respectively. To
measures. Importantly, the hexapeptide PAR1 agonist HsPAR150/55
further evaluate the involvement of the classic MAPK(SFLLRN) also mimicked these effects at 24 hours (data not shown).
pathway, we also directly tested the ability of thrombin
to activate ERK1/2. Both thrombin and PAR1 peptide
agonists increased ERK1/2 phosphorylation (Fig. 7A)
Thrombin’s effect on total HK activity and activity (Fig. 7B) within five minutes. Cellular PKC
is PTX-insensitive depletion by prolonged (24 hours) exposure to 1 mmol/L
G-protein–coupled receptors typically activate a single PMA completely inhibited the increases in ERK1/2
type of G protein. PAR1, however, is known to couple phosphorylation (Fig. 7A) and activity (Fig. 7B) ob-
with both PTX-sensitive Gi and PTX-insensitive Gq pro- served following thrombin or PAR1 peptide agonist
teins [22, 28, 29]. We therefore attempted to functionally treatment. As expected, thrombin’s ability to activate
characterize the type of G-protein interaction responsi- ERK1/2 was also blocked by PD98059 inhibition of
ble for mediating activated PAR1’s effect on HK activity. MEK1/2 (data not shown).
To this end, we tested the ability of 100 ng/mL PTX to
influence total HK activity at 24 hours. As shown in Thrombin-stimulated HK activity requires both
Figure 5, continuous PTX exposure had no significant ongoing gene transcription and de novo
effect on either basal or stimulated HK activities. protein synthesis
We have previously shown that phorbol esters increaseSer-Thr kinase inhibition attenuates thrombin-induced
mesangial cell HK activity within 12 to 24 hours via amesangial cell HK activity
mechanism that requires both ongoing gene transcrip-Thrombin is also a well-known activator of PKC in
tion and de novo protein synthesis [15]. To test whethercultured mesangial cells, and general Ser-Thr kinase inhi-
thrombin-stimulated HK activity exhibits similar re-bition by H-7 has been shown to inhibit some of the
quirements, we tested both the general transcriptionalcellular effects of thrombin in this cell type [30]. We
inhibitor DRB and the general translational inhibitortherefore tested H-7 for the ability to inhibit thrombin-
CHX for the ability to block HsPAR142/55-induced HKinduced HK activity in cultured mesangial cells. To this
activity. As with phorbol esters, both agents completelyend, we employed H-7 concentrations (25 to 50 mmol/L)
prevented the increase in HK activity normally seen fol-previously shown to be effective in blocking PKC activa-
lowing PAR1 activation (Table 1). A small, but signifi-tion and thrombin action in this cell type without ad-
cant, inhibition of basal HK activity was also observedversely affecting cell viability with prolonged 24-hour
following a 24-hour exposure to 20 mmol/L DRB, consis-exposure [30, 31]. As shown in Figure 6, 50 mmol/L H-
7 prevented the increase in HK activity by approximately tent with our previously reported observations [15].
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Fig. 5. PAR1-mediated HK induction by
thrombin is not pertussis toxin (PTX) inhibit-
able. Total HK activity was increased in mes-
angial cells stimulated by either thrombin
(1 U/mL) or the hexapeptide PAR1 agonist
HsPAR150/55 (SFLLRN; 100 mmol/L) for 24
hours (*P , 0.05 vs. unstimulated controls).
The presence of 100 ng/mL PTX had no sig-
nificant effect (P 5 NS) on either stimulated
or unstimulated HK activities. The depicted
data represent the mean 6 SEM of at least
four independent experiments. Symbols are:
(j) –PTX; ( ) 1 100 ng/mL PTX.
Increases in total HK activity are accompanied by P 5 NS), 110 6 6% (N 5 5, P 5 NS), 104 6 16% (N 5
increased Glc metabolism 3, P 5 NS), 98% (N 5 1), and 93% (N 5 1) of control
values, respectively. Similarly, cells exposed to 1 nmol/LWe have also previously shown that the phorbol ester
or 1 mmol/L Ang II for 24 hours resulted in HK activitiesPMA increases Glc metabolism by cultured mesangial
that were 104 6 3% (N 5 3, P 5 NS) and 117 6 3%cells, as measured by net Glc disappearance and lactate
(N 5 4, P 5 NS) of unstimulated controls, respectively.accumulation in the culture medium, and that these
Control cells exposed to 1 mmol/L PMA and evaluatedchanges temporally correspond to PMA-induced in-
in parallel uniformly increased HK activity as describedcreases in total HK activity [15]. To confirm that throm-
previously [15].bin-induced changes in total HK activity were also asso-
ciated with changes in mesangial cell Glc metabolism,
we evaluated the effect of thrombin on these parameters. DISCUSSION
As shown in Figure 8, both thrombin and the active
In addition to its central role in hemostasis, thrombinphorbol ester PDD mimicked the effect of PMA on
regulates a number of important cellular responses toGlc metabolism, whereas the inactive 4a-stereoisomer
vascular injury, including cell growth, cell migration, andof PDD (4a-PDD), which is incapable of activating PKC
matrix accumulation. Although best characterized in[32], did not.
platelets [34, 35] and in vascular endothelial cells [36],
thrombin’s cellular actions have been demonstrated inThe observed increases in mesangial cell HK activity
are specific for thrombin a variety of other cell types [37–40], including glomerular
mesangial cells [30, 33, 41–43]. These diverse cellularFinally, we tested the ability of other activators of
effects require thrombin’s proteolytic activity and arePKC to mimic the effects of phorbol esters and thrombin
largely mediated by specific interaction with one or moreon mesangial cell HK activity. The vasoactive peptides
recently identified members of the protease-activated re-angiotensin II (Ang II) and endothelin-1 (ET-1) are po-
ceptor family (PARs). In addition to being a potent mes-tent mesangial cell mitogens that share several common
angial cell mitogen [30, 41, 44], thrombin has also beensignaling intermediates with thrombin in this cell type,
shown to alter a number of important mesangial cellincluding PKC [33]. We therefore tested the ability of
functions such as contraction [44], prostaglandin E2 pro-both Ang II and ET-1 to influence total HK activity in
duction [44], and expression of both tissue-type plasmin-cultured mesangial cells. Interestingly, both Ang II and
ogen activator and plasminogen activator inhibitor 1 [30].ET-1 failed to mimic the effects of thrombin or PAR1
The G-protein–coupled heptaspanning PAR1 thrombin re-peptide agonists on HK activity. In fact, 24-hour expo-
ceptor is strongly expressed in mesangial cells [21, 22]sure to 0.1, 1, 10, 100, 200, 500, or 1000 nmol/L ET-1
and mediates a number of these effects [30, 33, 41, 44–46].resulted in total HK activities 96 6 5% (N 5 4, P 5
NS), 103 6 10% (N 5 4, P 5 NS), 99 6 10% (N 5 4, The present demonstration of thrombin-induced HK
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Fig. 7. Thrombin and PAR1 peptide agonists activate ERK1/2 via a
PKC-dependent mechanism. (A) Both total ERK2 and phospho-
ERK1/2 were detected and quantitated by parallel immunoblot analyses
of lysates prepared from cells exposed to thrombin (1 U/mL) or the
14-mer PAR1 peptide agonist HsPAR142/55 (SFLLRNPNDKYEPF; 100
mmol/L) for five minutes. Both thrombin and HsPAR142/55 were capable
of increasing the specific phosphorylation of ERK1/2, and these effects
were inhibited by antecedent PKC depletion resulting from prior 24-
hour exposure to 1 mmol/L PMA. (B) Total ERK1/2 activity was also
assayed in whole cell lysates as the ability of dual-phosphorylated
ERK1/2 immunoprecipitates to phosphorylate an Elk-1 fusion protein
in vitro (Elk-1-P). The duplicate, slower migrating band observed in
stimulated cell lysates represents a hyperphosphorylated form of the
Elk-1-P fusion protein. Both thrombin (1 U/mL) and the hexapeptide
PAR1 agonist HsPAR150/55 (SFLLRN; 100 mmol/L) were capable of
increasing ERK1/2 activity within five minutes. Increases in ERK1/2
activity uniformly paralleled increases in ERK1/2 phosphorylation and
were similarly blocked by antecedent PKC depletion. Representative
experiments, repeated at least four times with identical results, are
depicted.
activity represents a previously unreported cellular effect
of this important serine protease on mesangial cells, as
well as a novel mechanism of HK regulation. Thrombin
increased mesangial cell HK activity in both a dose-
and time-dependent manner, and these changes were
accompanied by corresponding increases in net Glc utili-
zation and net lactate accumulation. The ability of re-
Fig. 6. H-7 inhibits thrombin-induced mesangial cell HK activity. (A)
combinant leech hirudins—specific inhibitors of throm-H-7 inhibited thrombin-induced HK activity at 24 hours in a dose-
dependent fashion and at concentrations known to inhibit PKC activity bin’s proteolytic activity—to prevent this increase in HK
(*P , 0.05). (B) A smaller, albeit statistically significant, effect was activity suggests specificity for thrombin and is compati-also observed on basal activity at higher concentrations of H-7. All
data are presented as the mean 6 SEM of at least four independent ble with the observation that thrombin’s cellular effects
determinations. are largely mediated by proteolytic activation of cell
surface thrombin receptors [22]. The ability of oligo-
peptide PAR1 agonists (for example, HsPAR142/55 and
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Table 1. Dependence of increased hexokinase (HK) activity following PAR1 activation on both ongoing gene transcription and de novo
protein synthesis
No inhibitors 1CHX 10 mg/mL 1DRB 20 mmol/L
Unstimulated cells 100% 9762% 8464%a
HsPAR142/55-simulated cells 160614%a 8165%b 10568%b
Total HK activity was measured at 24 hours in cells treated with the PAR1 agonist HsPAR142/55 in the presence or absence of the general transcriptional inhibitor
dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) or the general inhibitor of translation, cycloheximide (CHX). Paired data from four independent experiments are
presented as mean activities relative to controls 6 SEM. The inhibitory effects of both CHX and DRB were dose dependent and maximal at the concentrations
depicted above (data not shown).
aP , 0.03 vs. unstimulated controls
bP , 0.04 vs. HsPAR142/55-stimulated cells
synthetic oligopeptides corresponding to the putative
NH2-terminal tethered ligands of PAR1 [20, 43, 50] and
PAR4 [48] have been shown to mimic thrombin’s effects
in cells expressing these receptors. Thus, the ability of
PAR1, but not PAR4, peptide agonists to mimic the
effect of thrombin on HK activity suggests that PAR1
activation is sufficient for thrombin’s effect on HK activ-
ity and that the PAR4 thrombin receptor does not con-
tribute substantially to this effect.
Unlike most G-protein–coupled receptors, which typi-
cally activate a single type of G protein, PAR1 has been
shown to couple with both PTX-sensitive Gi and PTX-
insensitive Gq effectors [28]. Consistent with these obser-
vations, both PTX-sensitive and PTX-insensitive cellular
effects of thrombin have been demonstrated in mesan-
gial cells and other cell types [22, 29]. The inability of
coadministered 0.1 mg/mL PTX to block the effects of
thrombin or PAR1 agonist peptides in our study suggests
that PTX-insensitive effectors such as Gq, G12, or Gs are
responsible for mediating the effects of PAR1 activation
on HK activity.
Fig. 8. Thrombin stimulates mesangial cell glucose (Glc) metabolism.
We have previously shown that phorbol esters initiateThrombin (d; 1 U/mL) increased both net Glc utilization and net lactate
accumulation by cultured mesangial cells (s; control). These changes an immediate chain of signaling events in murine mesan-
were observed between 18 and 24 hours following thrombin treatment gial cells that culminates in increased Glc-phosphorylat-
and temporally corresponded to maximal thrombin-induced changes in
ing capacity within 12 to 24 hours [15]. This effect re-total HK activity. Active (j; PDD 100 nmol/L), but not inactive (h;
4a-PDD 100 nmol/L), phorbol esters were found to mimic these effects quires both PKC and classic MAPK pathway activation,
of thrombin, consistent with a role for PKC activation in these changes. as well as ongoing gene transcription and de novo protein
All data are presented as the mean 6 SEM for at least four independent
synthesis. The corresponding endogenous activators ofexperiments.
the involved signaling pathway(s) in vivo, however, are
unknown. As a known activator of both PKC [16] and
the classic MAPK pathway [17], thrombin represents an
HsPAR150/55) [43, 45] to mimic this effect suggests speci- important candidate effector of these changes. In the
ficity for the PAR1 thrombin receptor. present studies, MEK1/2 inhibition by PD98059 abol-
Three distinct PARs—PAR1, PAR3, and PAR4—that ished both thrombin-induced and PAR1 peptide agonist-
are specifically activated by thrombin have recently been induced HK activity, suggesting the involvement of the
cloned and characterized [20, 47, 48]. Of these receptors, classic MAP kinase pathway. The ability of both throm-
renal expression has been demonstrated only for PAR1. bin and PAR1 peptide agonists to increase ERK1/2 phos-
The mechanism of thrombin receptor activation has been phorylation and activity is consistent with this interpreta-
reviewed elsewhere [49]. In brief, targeted cleavage of tion. The ability of antecedent PKC depletion to inhibit
each receptor’s extracellular NH2-terminus by thrombin ERK1/2 phosphorylation and activity also suggests a role
generates a new NH2-terminal “tethered ligand” that is for PKC activation in this process. The demonstration
capable of specific intramolecular interaction with, and that general inhibitors of gene transcription and transla-
tion (that is, DRB and CHX, respectively) are similarlyactivation of the receptor. Consistent with this model,
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capable of preventing increased HK activity following ties. As one of the principal cell types affected in glomer-
ular injury of various etiologies, it would be attractivePAR1 activation further suggests a related dependence
on ongoing gene transcription and de novo protein syn- to speculate that thrombin plays an important role not
only in mesangial cell Glc metabolism, but also in thethesis.
Taken together, these findings are consistent with the functional and structural changes that accompany injury.
The changes demonstrated herein are comparable inhypothesis that phorbol esters and thrombin induce mes-
angial HK activity via a common mechanism involving magnitude to those reported previously in the cortex of
animals with experimental diabetes and are compatiblethe sequential activation of PKC and the classic MAPK
pathway (Raf!MEK!ERK). Given the apparent com- with such a hypothesized role. Physiologic control of
thrombin’s actions is largely mediated at the level ofmon requirement for ongoing gene transcription, it
would also be attractive to speculate that activation of active thrombin generation [52], which is markedly in-
creased in the settings of vascular injury [52] and diabetesPKC and ERK1/2 by phorbol esters or thrombin ulti-
mately results in increased HK gene expression. Three [53]. Thus, thrombin’s actions are particularly relevant
to the understanding of metabolic responses to renalhigh-affinity HK isoforms (types I, II, and III) are ex-
pressed in the kidney [51], but their intrarenal expression or vascular injury. Our findings also suggest a specific
mechanism whereby cellular energy metabolism may bepatterns and cellular regulation are poorly understood.
Preliminary studies in our laboratory have suggested that coupled to thrombin receptor activation and cellular in-
mesangial cells express all three isoforms and HKII ap- jury responses. We therefore speculate that HKs may
pears to constitute the principal regulated isoform in this play a role in either the mediation of or the response to
cell type (abstract; Robey et al, J Am Soc Nephrol renal injury and that thrombin may contribute to this
10:57A, 1999). Both HKII and HKIII are low-abundance role.
renal isoforms, together accounting for only one third
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